Search for content, post, videos

Mendus announces positive Phase 2 data

Erik Manting

Mendus has reported positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel in acute myeloid leukemia (AML).

The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from the current standard of care in AML maintenance therapy, the company states.

“We are obviously very pleased with this latest update from the ADVANCE II trial,” says Erik Manting, CEO of Mendus. “We are moving ahead expeditiously to expand the clinical testing of vididencel in AML and to prepare for registrational studies. We will next study the combination with oral azacitidine in a larger trial including a comparator arm in our recently announced collaboration with the Australian Leukaemia and Lymphoma Group (ALLG).”


ADVANCE II is a Phase 2 monotherapy trial evaluating vididencel as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into first complete remission (CR1) through chemotherapy, but with measurable residual disease (MRD).

“Results from ADVANCE II further strengthen the case that vididencel represents one of the most promising AML maintenance therapies currently in development,” says Jeroen Rovers, CMO of Mendus. “Not only do these survival data exceed the historical survival rates observed with current standard of care maintenance therapy, but we have also amassed a significant body of immunomonitoring data that provides further evidence that vididencel treatment can lead to improved immune responses against residual disease and durable remissions in AML patients.”

Photo of Erik Manting: Mendus